Who was studied?
One patient with refractory metastatic, PD-L1-negative esophageal squamous cell carcinoma.
What does the publication report?
Systemic antitumor activity was described after treatment of metastatic lesions.
Safety findings
Severe pneumonia occurred after the combination treatment. This important safety signal accompanies the response report.
How should we interpret it?
A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review · DOI: 10.3389/fonc.2020.01625 · PMID: 33014817
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.